Liu Wei, Xu Jinhe, Lin Baoquan, Zhang Yabin, Xie Feilai, Zhou Chengzhi, Lai Guoxiang, Zhang Lei, Yu Zongyang
Department of Respiratory and Critical Care Medicine, Dongfang Hospital of Xiamen University, Fuzhou General Hospital of Fujian Medical University, The 900th Hospital of the Joint Logistic Support Force, PLA, Fuzhou, China.
Graduate College of Fujian Medical University, Fuzhou, China.
Ann Palliat Med. 2021 Jan;10(1):759-766. doi: 10.21037/apm-20-2137. Epub 2021 Jan 11.
Talaromyces marneffei (T. marneffei) is a pathogenic, thermally dimorphic fungus that can cause invasive infection and significant morbidity in immunocompromised patients, especially those with human immunodeficiency virus (HIV) or other immune defects. Currently, T. marneffei infection is understood to be not limited only to immunodeficient patients, as cases of immunocompromised patients or immunocompetent patients associated with T. marneffei infection have been increasingly reported in recent years. The exact mechanism is not yet clear. This study reports a case of an advanced lung adenocarcinoma patient with T. marneffei infection. The patient is a 59-year-old female with a 3-month history of coughing, expectoration, and progressive dyspnea. Computed tomography (CT) scans showed a mass in the left lower lung, multiple plaques and nodules in both lungs, and left pleural effusion. The patient was diagnosed with T. marneffei infection, as T. marneffei was found in both the bronchoalveolar lavage fluid (BALF) and the sputum. According to the pathology of the left lung lesion by transbronchial lung biopsy (TBLB) and contrast-enhanced brain magnetic resonance imaging (MRI), the patient was diagnosed with epidermal growth factor receptor (EGFR) mutation-positive stage Ⅳ lung adenocarcinoma (T4N3M1c). She received intravenous liposomal amphotericin B and oral itraconazole as anti-fungal treatments, meanwhile, icotinib was used as an anti-tumor treatment. Following treatment, CT re-examination showed that the mass was remarkably absorbed, and some of the lung nodules had disappeared. No relapse of T. marneffei infection was found during the follow-up. This case indicates that patients with malignant lung tumors may possibly become infected with T. marneffei. Sequential treatment of amphotericin liposome B followed by itraconazole is effective for lung cancer patients with T. marneffei infection.
马尔尼菲篮状菌(T. marneffei)是一种致病性的、温度双相型真菌,可在免疫功能低下的患者中引起侵袭性感染并导致严重发病,尤其是那些感染人类免疫缺陷病毒(HIV)或有其他免疫缺陷的患者。目前,人们认为马尔尼菲篮状菌感染不仅限于免疫缺陷患者,近年来,免疫功能低下患者或免疫功能正常患者感染马尔尼菲篮状菌的病例报告越来越多。确切机制尚不清楚。本研究报告了一例晚期肺腺癌患者合并马尔尼菲篮状菌感染的病例。该患者为一名59岁女性,有3个月咳嗽、咳痰及进行性呼吸困难病史。计算机断层扫描(CT)显示左下肺有一肿块,双肺有多个斑片及结节,左侧胸腔积液。该患者被诊断为马尔尼菲篮状菌感染,因为在支气管肺泡灌洗液(BALF)和痰液中均发现了马尔尼菲篮状菌。根据经支气管肺活检(TBLB)的左肺病变病理及对比增强脑磁共振成像(MRI),该患者被诊断为表皮生长因子受体(EGFR)突变阳性的Ⅳ期肺腺癌(T4N3M1c)。她接受了静脉注射脂质体两性霉素B和口服伊曲康唑作为抗真菌治疗,同时,使用埃克替尼作为抗肿瘤治疗。治疗后,CT复查显示肿块明显吸收,部分肺结节消失。随访期间未发现马尔尼菲篮状菌感染复发。该病例表明,恶性肺肿瘤患者可能会感染马尔尼菲篮状菌。脂质体两性霉素B序贯伊曲康唑治疗对马尔尼菲篮状菌感染的肺癌患者有效。